# Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

> **NCT05640609** · PHASE1,PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Stomach Neoplasm

## Interventions

- **COMBINATION_PRODUCT:** Capeox regimen combined with Sintilimab and Bevacizumab

## Key facts

- **NCT ID:** NCT05640609
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-10
- **Primary completion:** 2024-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05640609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05640609, "Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05640609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*